Form 4: 4D Molecular Therapeutics Executive Sells Shares

David Kirn, Director and Officer of 4D Molecular Therapeutics, Inc., reported a transaction involving the sale of 1,922 shares of common stock on June 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• David Kirn, who holds positions as Director and Officer at 4D Molecular Therapeutics, Inc., has reported a sale of 1,922 shares of common stock.
• The transaction occurred on June 1, 2026, and was conducted under a Rule 10b5-1 trading plan adopted by Mr. Kirn on January 9, 2026.
• The shares were sold at a weighted average price of $10.0197, with individual trades ranging from $10.00 to $10.055.
• Following this transaction, Mr. Kirn beneficially owns 1,057,231 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally. While an insider sale can sometimes be perceived negatively, the execution under a 10b5-1 plan suggests a pre-determined strategy rather than a reaction to adverse company news.

Negatives

• An executive sold a portion of their holdings, which could be perceived negatively by the market, although it was executed under a pre-planned trading strategy.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. The execution of a 10b5-1 plan indicates pre-planned trading activity, often used by executives to diversify holdings or manage personal finances without implying negative sentiment about the company's prospects.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may lead to short-term market perception shifts, though the 10b5-1 plan mitigates concerns about insider knowledge.
• Employees: No direct impact is indicated.
• Creditors: No direct impact is indicated.
• Suppliers: No direct impact is indicated.
• Customers: No direct impact is indicated.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, 10b5-1 Plan, Stock Sale, 4D Molecular Therapeutics, FDMT, David Kirn, Beneficial Ownership